fda safety communication semaglutide naion 2025 June Drug Update: Recalls of generic Bactrim, Carvedilol, Zicam nasal swabs; Depakote and Lamictal warnings; GLP-1 drugs and eye disease; medication tips Ozempic® NAION Lawsuit | Attorneys

Aim for 2030 minutes of moderate exercise most days to support both blood sugar and blood pressure control

Tirzepatide is the current "king" of approved weight loss drugs, but dual glucagon agonists (like Mazdutide) are theoretically capable of surpassing it by burning more calories

Facial Side Effects Many patients using semaglutide injections have reported experiencing facial side effects, colloquially known as Ozempic Face. This term typically refers to noticeable changes in facial contours and subcutaneous fat loss, leading to a thinner, more gaunt appearance

It uses the same dual GIP/GLP-1 approach as Mounjaro, with similar dosing and titration schedules (starting at 2.5 mg and potentially increasing up to 15 mg)